Discordance between the triglyceride glucose index and fasting plasma glucose or HbA1C in patients with acute coronary syndrome undergoing percutaneous coronary intervention predicts cardiovascular events: a cohort study from China

[21] Reith C(2018)Fourth universal definition of myocardial infarction Circulation 138 e618-361

[22] Cannon CP(2007)Clinical end points in coronary stent Trials. A case for standardized definitions Circulation 115 2344-315

[23] Blazing MA(2015)2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) Circulation 132 302-3104

[24] Giugliano RP(2016)2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J 37 267-323

[25] McCagg A(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 39 3021-1265

[26] White JA(2019)ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur Heart J 2020 255-1573

[27] Theroux P(2016)Association of triglycerides and new lipid markers with the incidence of hypertension in a Spanish cohort J Hypertens 34 1257-253

[28] Sabatine MS(2017)Triglyceride and glucose (TyG) index as a predictor of incident hypertension: a 9-year longitudinal population-based study Lipids Health Dis 16 175-1676

[29] Giugliano RP(2016)Predictive value of triglyceride glucose index for the risk of incident diabetes: a 4-year retrospective longitudinal study PLoS ONE 11 e0163465-105

[30] Keech AC(2020)High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study Cardiovasc Diabetol 19 53-935

[21] Reith C(2018)Fourth universal definition of myocardial infarction Circulation 138 e618-361

[22] Cannon CP(2007)Clinical end points in coronary stent Trials. A case for standardized definitions Circulation 115 2344-315

[23] Blazing MA(2015)2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards) Circulation 132 302-3104

[24] Giugliano RP(2016)2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) Eur Heart J 37 267-323

[25] McCagg A(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 39 3021-1265

[26] White JA(2019)ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur Heart J 2020 255-1573

[27] Theroux P(2016)Association of triglycerides and new lipid markers with the incidence of hypertension in a Spanish cohort J Hypertens 34 1257-253

[28] Sabatine MS(2017)Triglyceride and glucose (TyG) index as a predictor of incident hypertension: a 9-year longitudinal population-based study Lipids Health Dis 16 175-1676

[29] Giugliano RP(2016)Predictive value of triglyceride glucose index for the risk of incident diabetes: a 4-year retrospective longitudinal study PLoS ONE 11 e0163465-105

[30] Keech AC(2020)High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study Cardiovasc Diabetol 19 53-935